Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 26,575 shares of the company’s stock, valued at approximately $6,687,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC raised its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. raised its position in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the last quarter. Ieq Capital LLC raised its position in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its stake in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HSBC reissued a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Bank of America boosted their target price on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Cantor Fitzgerald raised their price target on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $275.50.

AbbVie Stock Up 1.0%

Shares of AbbVie stock opened at $251.20 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market cap of $443.82 billion, a PE ratio of 70.96, a P/E/G ratio of 0.82 and a beta of 0.30. The business’s fifty day moving average is $244.51 and its two-hundred day moving average is $225.96.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm posted $2.97 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.